Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics

Corvus Pharmaceuticals, Inc. (CRVS): $1.01

0.02 (+2.01%)

POWR Rating

Component Grades













Add CRVS to Watchlist
Sign Up

Industry: Biotech



in industry

CRVS Stock Price Chart Interactive Chart >

Price chart for CRVS

CRVS Price/Volume Stats

Current price $1.01 52-week high $9.54
Prev. close $0.99 52-week low $0.75
Day low $0.97 Volume 248,400
Day high $1.06 Avg. volume 282,823
50-day MA $1.11 Dividend yield N/A
200-day MA $2.54 Market Cap 47.02M

Corvus Pharmaceuticals, Inc. (CRVS) Company Bio

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.

CRVS Latest News Stream

Event/Time News Detail
Loading, please wait...

CRVS Latest Social Stream

Loading social stream, please wait...

View Full CRVS Social Stream

Latest CRVS News From Around the Web

Below are the latest news stories about Corvus Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRVS as an investment opportunity.

Corvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in China

Corvus Pharmaceuticals'' (CRVS) partner Angel Pharmaceuticals has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for

Seeking Alpha | January 14, 2022

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China. “We are excited that Angel has begun to enroll patients in its

Yahoo | January 13, 2022

Insiders who bought stock earlier this year lose -US$118k as Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) drops to US$112m

The recent 12% drop in Corvus Pharmaceuticals, Inc.'s ( NASDAQ:CRVS ) stock could come as a blow to insiders who...

Yahoo | January 1, 2022

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

Data Presented in Poster Presentation at American Society of Hematology Annual MeetingBURLINGAME, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus host disease (aGVHD) in patients receiving allogeneic hematopoietic cell transplantation (bone marrow transplant

Yahoo | December 13, 2021

Analysts Expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Post -$0.22 EPS

Wall Street analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report earnings per share (EPS) of ($0.22) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.17). Corvus Pharmaceuticals posted []

Dakota Financial News | December 10, 2021

Read More 'CRVS' Stories Here

CRVS Price Returns

1-mo -4.72%
3-mo -48.73%
6-mo -54.71%
1-year N/A
3-year -84.46%
5-year -91.90%
YTD -58.09%
2021 -32.30%
2020 -34.56%
2019 48.23%
2018 -64.58%
2017 -27.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.522 seconds.